23andMe is a leading genetic testing and healthcare company that helps consumers access, understand, and benefit from the human genome. 23andMe offers 2 key products to consumers: “Ancestry Test Kits” and “Ancestry + Genetic Health Test Full Suite Kits”. Through these testing products, customers can receive comprehensive risk assessment report on their likelihood of developing genetically influenced diseases, including Parkinson’s, Alzheimer’s, Breast Cancer, Ovarian Cancer, Prostate Cancer, diabetes, and a number of other chronic illnesses. As of December 2020, the Company’s products are offered in 52 countries, its number of genetic profiles have surpassed 12 million profiles, and is approved to issue more than 55 health reports. 23andMe maintains strategic co-drug development partnerships with large-scale pharmaceutical companies such as Genentech, Pfizer, and GSK. Additionally, 23andMe is currently developing 13 proprietary candidates within its own drug pipeline.